has entered a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo (axatilimab-csfr), a treatment for chronic graft-versus-host disease (GVHD).
The deal positions Syndax to launch two medicines and pursue further indications.
Syndax has received $350m upfront in return for a 13.8% royalty on Niktimvo鈥檚 net US sales. 聽
Royalty payments to Royalty Pharma will cease once they reach 2.35 times the initial amount.
Syndax’s financial and legal advisors respectively were & Co and Cooley. Gibson, Dunn & Crutcher, and Dechert advised Royalty Pharma.
Syndax CEO Michael Metzger stated: “We expect this transaction to fund us through profitability, while ensuring that we continue to participate in the profits from Niktimvo and retain the upside of its future growth.鈥�
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataNiktimvo, an anti-colony stimulating factor 1 receptor (CSF-1R) antibody, has received approval in the US for treating chronic GVHD in adult and paediatric patients weighing a minimum of 40kg after at least two previous systemic treatment failures.
In 2016, Syndax obtained exclusive global rights from to develop and commercialise axatilimab.
In September 2021, Syndax and entered an exclusive global co-development and co-commercialisation licence agreement for axatilimab in chronic GVHD and possible future indications.
Royalty Pharma founder and CEO Pablo Legorreta stated: “We are excited to partner with Syndax, an innovative oncology company with an exciting pipeline.
鈥淲e look forward to Syndax and their partner Incyte launching Niktimvo soon and bringing this important medicine to GVHD patients.”
Niktimvo will be co-commercialised by Syndax and Incyte in the US, with a launch expected by the first quarter of 2025. Incyte holds exclusive rights to commercialise outside the US.
Axatilimab is currently being evaluated in frontline combination studies for chronic GVHD.
A Phase II trial in combination with ruxolitinib is active, and a Phase III trial with steroids is in the planning stages.
Axatilimab is undergoing a Phase II trial for idiopathic pulmonary fibrosis.
